Loading stock data…
$1.06-0.02 (-1.85%)
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
Cocrystal Pharma, Inc. in the Healthcare sector is trading at $1.07 with a market capitalization of $21M. Wall Street consensus targets $8.00 (3 analysts), implying a +647.7% move over the next 12 months. The stock is currently 47% below its 52-week high of $2.03, remaining 3.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105,000↓ | $225,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.18M↓ | -$2.36M↑ | -$2.48M↓ | -$2.09M↑ | -$2.11M |
| Net Income | -$3.16M↓ | -$2.30M↑ | -$2.43M↓ | -$2.05M↑ | -$2.06M |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create a...